Jilin Aodong Pharmaceutical Group Co., Ltd. (000623.SZ)
CNY 18.04
(0.22%)
CNY 18.04
(0.22%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 68.06 Million | 423.85 Million | 324.84 Million | 390.4 Million | 379.45 Million | 347.63 Million |
| Net Income | 1.44 Billion | 1.8 Billion | 1.77 Billion | 1.69 Billion | 1.39 Billion | 924.65 Million |
| Depreciation & Amortization | 233.87 Million | 225.62 Million | 204.15 Million | 195.46 Million | 194.02 Million | 186.87 Million |
| Deferred income taxes | -3.82 Million | -123.3 Million | -46.59 Million | -12.12 Million | 1.41 Million | -25.51 Million |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -422.38 Million | -169.95 Million | -67.95 Million | 90.19 Million | -108.33 Million | -240.92 Million |
| Other non-cash items | -1.18 Billion | -1.43 Billion | -1.58 Billion | -1.58 Billion | -1.09 Billion | -522.96 Million |
| Investing Cash Flow | 763.61 Million | -553.21 Million | -710.4 Million | 185.2 Million | 157.88 Million | -1.75 Billion |
| Investments in PPE | -419.52 Million | -270.96 Million | -313.3 Million | -227.38 Million | -222.39 Million | -245.3 Million |
| Acquisitions | 34.61 Million | -2.13 Million | 36.93 Million | -953.96 Thousand | 1.3 Million | 22.61 Million |
| Investment purchases | -10.55 Billion | -7.64 Billion | -9.08 Billion | -7.97 Billion | -2.76 Billion | -2.36 Billion |
| Sales/Maturities of investments | 10.91 Billion | 7.44 Billion | 8.63 Billion | 7.6 Billion | 2.82 Billion | 2.62 Billion |
| Other Investing Activities | 788 Million | -80.91 Million | 15 Million | 782.42 Million | 320 Million | -1.78 Billion |
| Financing Cash Flow | -549.2 Million | -171.07 Million | -362.4 Million | -283.5 Million | -259.76 Million | 2.13 Billion |
| Debt repayment | -651.69 Million | -374.92 Million | -342.37 Million | -21.56 Million | -30.55 Million | -56.05 Million |
| Dividends payments | -338.08 Million | -341.09 Million | -227.76 Million | -231.79 Million | -232.6 Million | -351.46 Million |
| Common Stock Repurchased | -149.99 Million | -170.03 Million | -100 Million | -300.03 Million | - | - |
| Common Stock Issuance | - | 170.03 Million | 100 Million | 300.03 Million | - | - |
| Other Financing Activities | -149.99 Million | 581.61 Million | 235.68 Million | -9.64 Million | 11.62 Million | 2.54 Billion |
| Accounts receivables | -304.32 Million | -189.01 Million | 6.42 Million | 58.66 Million | 40.5 Million | -234.56 Million |
| Accounts payables | -97.31 Million | 443.57 Million | 31.82 Million | 64.18 Million | -142.63 Million | 110.06 Million |
| Inventory | -16.92 Million | -301.22 Million | -59.61 Million | -20.53 Million | -7.61 Million | -90.9 Million |
| Other working capital | -3.82 Million | -123.3 Million | -46.59 Million | -12.12 Million | 1.41 Million | -150.02 Million |
| Cash at beginning of period | 1.43 Billion | 1.74 Billion | 2.48 Billion | 2.19 Billion | 1.91 Billion | 1.19 Billion |
| Cash at end of period | 1.71 Billion | 1.43 Billion | 1.74 Billion | 2.48 Billion | 2.19 Billion | 1.91 Billion |
| Capital Expenditure | -419.52 Million | -270.96 Million | -313.3 Million | -227.38 Million | -222.39 Million | -245.3 Million |
| Effect of forex changes on cash | -718.51 Thousand | -4.11 Million | 1.72 Million | 4.02 Million | -1.85 Million | -6.77 Million |
| Net cash flow / Change in cash | 281.75 Million | -304.54 Million | -746.23 Million | 296.13 Million | 275.72 Million | 726.29 Million |
| Free Cash Flow | -351.46 Million | 152.89 Million | 11.54 Million | 163.02 Million | 157.06 Million | 102.33 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 706.65 Million | 393.79 Million | 143.66 Million | 1.44 Billion | 185.6 Million | 211.09 Million |
| Depreciation & Amortization | - | 59.69 Million | 59.69 Million | 233.87 Million | 61.48 Million | -113.05 Million |
| Deferred income taxes | - | - | - | -3.82 Million | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | -39.49 Million | - | -422.38 Million | -439.81 Million | 401.33 Million |
| Other non-cash items | -226.89 Million | -298.8 Million | -155.82 Million | -1.18 Billion | 545.74 Million | -498.59 Million |
| Investing Cash Flow | 382.41 Million | -27.02 Million | -89.18 Million | 763.61 Million | -279.29 Million | 345.15 Million |
| Investments in PPE | -39.63 Million | -101.87 Million | -84.88 Million | -419.52 Million | -153.99 Million | -153.03 Million |
| Acquisitions | 313.31 Thousand | 569.45 Thousand | 159.65 Thousand | 34.61 Million | 0.65 | 30.55 Million |
| Investment purchases | -2.86 Billion | -330.15 Million | -129.29 Million | -10.55 Billion | -2.33 Billion | -1.1 Billion |
| Sales/Maturities of investments | 3.29 Billion | 361.52 Million | 124.83 Million | 10.91 Billion | 2.21 Billion | 1.57 Billion |
| Other Investing Activities | 313.31 Thousand | 569.45 Thousand | -3.7 Million | 788 Million | 17.58 Thousand | 0.98 |
| Financing Cash Flow | -1.11 Billion | 430.41 Million | 13.39 Million | -549.2 Million | -212.39 Million | -426.45 Million |
| Debt repayment | -387.62 Million | -444.94 Million | -85.7 Million | -651.69 Million | -106.35 Million | -132.18 Million |
| Dividends payments | -726.75 Million | -14.52 Million | -72.3 Million | -338.08 Million | -338.08 Million | -344.68 Million |
| Common Stock Repurchased | - | - | - | -149.99 Million | -149.99 Million | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -1.8 Million | -14.52 Million | -72.3 Million | -149.99 Million | -100.01 Million | 50.41 Million |
| Accounts receivables | - | 79.32 Million | - | -304.32 Million | -304.32 Million | 365.44 Million |
| Accounts payables | - | - | - | -97.31 Million | - | -3.44 Million |
| Inventory | - | -100.82 Million | - | -16.92 Million | -16.92 Million | 35.88 Million |
| Other working capital | - | -17.99 Million | - | -3.82 Million | -118.56 Million | 3.44 Million |
| Cash at beginning of period | 2.02 Billion | 1.63 Billion | 1.72 Billion | 1.43 Billion | 1.85 Billion | 1.93 Billion |
| Cash at end of period | 1.26 Billion | 2.02 Billion | 1.63 Billion | 1.71 Billion | 1.71 Billion | 1.85 Billion |
| Capital Expenditure | -39.63 Million | -101.87 Million | -84.88 Million | -419.52 Million | -153.99 Million | -153.03 Million |
| Effect of forex changes on cash | 194.81 Thousand | -160.78 Thousand | -7683.11 | -718.51 Thousand | 287.08 Thousand | 175.21 Thousand |
| Net cash flow / Change in cash | -760.06 Million | 395.61 Million | -87.95 Million | 281.75 Million | -138.39 Million | -80.34 Million |
| Free Cash Flow | 440.12 Million | -66.58 Million | -97.04 Million | -351.46 Million | 199.01 Million | -152.25 Million |
EVOK
NGRD3
HVID
USAC
ABEV3
BRCR11